Composition for Neural Precursor Cell Therapy, Singapore
Summary
The United States Patent and Trademark Office published patent application US20260108561A1, filed by National University of Singapore (assignee) on October 3, 2023. The application covers a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into neurological injury or disease sites, comprising a gel forming molecule and a CCR5 antagonist. Also disclosed are methods of treating neurological injuries using NPC transplantation with this composition and a kit containing the composition, artificial cerebral spinal fluid, CaCl2, and thrombin.
“Disclosed is a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into a neurological injury or disease site, the composition comprising: (a) a gel forming molecule; and (b) a chemokine receptor type 5 (CCR5) antagonist.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published a new patent application (US20260108561A1) filed by National University of Singapore on October 3, 2023, covering a composition for cell transplantation therapy. The composition comprises a gel forming molecule and a chemokine receptor type 5 (CCR5) antagonist designed to support survival and differentiation of neural precursor cells grafted into neurological injury or disease sites. The application also discloses methods of treatment using NPCs mixed with this composition and a kit containing the composition, artificial cerebral spinal fluid, CaCl2, and thrombin.
For biotechnology and pharmaceutical companies developing cell-based therapies for neurological conditions, this published application signals potential prior art in the NPC transplantation space. Researchers and developers working on similar CCR5 antagonist applications for neural repair should conduct freedom-to-operate analyses. The CPC classifications (A61K 35/30, A61K 33/06, A61K 38/4833, A61P 25/28) indicate pharmaceutical compositions for nervous system disorders, which may inform competitive patent landscapes.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF
Application US20260108561A1 Kind: A1 Apr 23, 2026
Assignee
NATIONAL UNIVERSITY OF SINGAPORE
Inventors
Suchun ZHANG, Zhifu WANG
Abstract
Disclosed is a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into a neurological injury or disease site, the composition comprising: (a) a gel forming molecule; and (b) a chemokine receptor type 5 (CCR5) antagonist. Also disclosed is a method of treating a neurological injury or disease of a subject, comprising (a) mixing NPCs with the composition as disclosed herein; and (b) administering a mixture of the NPCs and the composition into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Also disclosed is use of a mixture of NPCs and the composition as disclosed herein in the manufacture of a medicament for treating a neurological injury or disease of a subject, wherein the mixture is to be administered into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Further disclosed is a kit for use in supporting survival and differentiation of NPCs grafted into a neurological injury or disease site, the kit comprising: (a) the composition as disclosed herein; (b) artificial cerebral spinal fluid (a-CSF); (c) CaCl2; and (d) thrombin.
CPC Classifications
A61K 35/30 A61K 33/06 A61K 38/4833 A61P 25/28
Filing Date
2023-10-03
Application No.
19117699
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.